Quantitative detection method of T cell linked bispecific antibody based on bioluminescence reporter gene and application of quantitative detection method

A bioluminescent reporter gene-based method for quantifying T cell engaging bispecific antibodies like belintox addresses high cost and sample volume issues, enabling efficient and accurate quantification with Jurkat cells expressing luciferase under the IL-2 promoter.

CN119061114APending Publication Date: 2024-12-03SHANDONG UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411335156.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-24
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current methods for quantifying T cell engaging bispecific antibodies like belintox are limited by high costs, technical requirements, and the need for large serum/plasma samples, making them impractical for children and lacking commercial availability of necessary cell lines, especially in China.

Method used

A quantitative detection method using bioluminescent reporter genes, specifically constructing Jurkat cells with a luciferase gene regulated by the IL-2 promoter, which express luciferase upon antibody engagement, allowing for rapid and sensitive quantification through bioluminescence detection.

Benefits of technology

The method provides accurate, precise, and cost-effective quantification of belintox with simple steps, suitable for various samples, overcoming the limitations of existing techniques.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061114A_ABST
    Figure CN119061114A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological detection, and particularly relates to a quantitative detection method of a T cell linked bispecific antibody based on a bioluminescence reporter gene and application of the quantitative detection method. Specifically, Bellintoohm is used as a representative, target cells and effector cells related to an antibody to be detected are constructed, and reporter genes capable of expressing luciferase are combined in the effector cells. According to the present invention, the expression of the bioluminescence reporter gene (luciferase gene) is promoted through the interaction between the antibody to be detected and the surface protein (CD19) of the target cell and the surface protein (CD3) of the effector cell, such that the activity of the antibody to be detected is indicated so as to achieve the rapid, efficient and quantitative detection of the Bellintoeu, such that the good practical application value is provided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biological detection technology, and specifically relates to a quantitative detection method of T cell engaging bispecific antibodies based on bioluminescent reporter genes and its application. Background Art

[0002] The information disclosed in the background of the invention is only intended to enhance the understanding of the overall background of the invention and should not be necessarily regarded as an acknowledgment or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Immunotherapy aims to boost a patient's own immune system to fight disease. In recent years, various immunotherapy strategies aimed at inducing, enhancing or engineering T cell responses have emerged as promising approaches for treating cancer and autoimmune diseases.

[0004] Take Belintoq as an example, it is a new type of T cell engaging bispecific single-chain antibody (BiTE) targeting CD19 / CD3. Belintoq mediates the formation of synapses between CD3+T cells and CD19+ target cells, transiently connecting malignant cells with T cells to induce T cells to target and kill the bound malignant cells.

[0005] Currently, there is only a combined method for quantification of belintox in human serum by cytotoxicity assay followed by flow cytometry to determine the level of CD69 activation on the surface of T cells. Raji lymphoma line as target cells and human T cell line HPBALL as effector cells were incubated in the presence of serial dilutions of calibration standards of belintox in serum or plasma. After co-incubation, cells were labeled with fluorescent antibodies against the T cell activation marker CD69 and detected by flow cytometry.

[0006] However, there are still some limitations in practical application. Flow cytometry can detect many types of samples, with a faster detection speed and a larger number of analyzed samples. But in addition to the high cost and high technical requirements of flow cytometry itself, it requires sufficient serum / plasma sample volume for detection, which is somewhat difficult for children. More importantly, there are no commercially available HPBALL cells in China, and it is impossible to quantify the belinto-one macromolecule. Therefore, it is still difficult to detect the concentration of belinto-one. Summary of the invention

[0007] In view of the deficiencies in the prior art, the object of the present invention is to provide a quantitative detection method and application of a T cell-engaged bispecific antibody based on a bioluminescent reporter gene. Specifically, the present invention is represented by Bellinto, by constructing target cells and effector cells related to the antibody to be detected, and combining a reporter gene capable of expressing luciferase in the effector cell. Through the interaction between the antibody to be detected and the surface protein (CD19) of the target cell and the surface protein (CD3) of the effector cell, the expression of the bioluminescent reporter gene (luciferase gene) is promoted, which is used to indicate the activity of the antibody to be detected, thereby achieving the purpose of rapid and efficient quantitative detection of Bellinto. Based on the above research results, the present invention is completed.

[0008] In order to achieve the above technical objectives, the technical solution provided by the present invention is as follows:

[0009] The first aspect of the present invention provides a quantitative detection method for T cell engaging bispecific antibodies based on bioluminescent reporter genes, the quantitative detection method comprising:

[0010] Constructing target cells and effector cells; adding a sample to be tested thereto for incubation, wherein the target cells are Raji cells (CD19), the effector cells are Jurkat cells (CD3), and the effector cells are luciferase Jurkat-luc cells regulated by the IL-2 promoter;

[0011] The luciferase signal is detected to indicate T cell engagement of the bispecific antibody.

[0012] The second aspect of the present invention provides the application of the above quantitative detection method in the pharmacokinetic study of T cell engaging bispecific antibodies.

[0013] Wherein, the T cell engaging bispecific antibody may be belintox.

[0014] Beneficial technical effects of one or more of the above technical solutions:

[0015] The above technical scheme uses Jurkat T cell line, which expresses luciferase gene under IL-2 promoter. When Jurkat cells are activated, luciferase is expressed in a dose-dependent manner of belintoou monoclonal antibody. The level of belintoou monoclonal antibody can be quantified by measuring bioluminescence. The method has simple steps, easy operation, sensitive detection, low cost, and can be well used for quantification of belintoou monoclonal antibody serum samples.

[0016] The above technical solution has constructed a Jurkat cell line (Jurkat-luc) with a luciferase reporter gene regulated by the IL-2 promoter. The luciferase level increases in a drug concentration-dependent manner, and the methodological verification of quantitative detection has been completed. This method has good accuracy and precision, and therefore has good practical application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0018] Figure 1 It is a lentiviral vector in the embodiment of the present invention.

[0019] Figure 2 It is the intensity of Jurkat-luc monoclonal AG luciferase in the example of the present invention.

[0020] Figure 3 This is the PHA-RLU curve in the embodiment of the present invention.

[0021] Figure 4 This is the Bellinto-RLU curve in the embodiment of the present invention.

[0022] Figure 5 1 is the Bellintosh-RLU curve under different plasma conditions in the examples of the present invention.

[0023] Figure 6 1 is the Bellintosh-RLU curve of different blood conditions in the embodiment of the present invention.

[0024] Figure 7 1 is the Bellinto-RLU curve under different serum conditions in the examples of the present invention.

[0025] Figure 8 This is the fitting curve of the serum drug concentration of Bellintosu in the embodiment of the present invention. DETAILED DESCRIPTION

[0026] It should be noted that the following detailed descriptions are all illustrative and intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0027] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit exemplary embodiments according to the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0028] The present invention is further described in conjunction with specific examples. The following examples are only for explaining the present invention and are not intended to limit the content thereof. If the specific experimental conditions are not specified in the examples, they are usually carried out according to conventional conditions or the conditions recommended by the reagent company; the reagents and consumables used in the following examples, unless otherwise specified, can all be obtained from commercial sources.

[0029] In a typical embodiment of the present invention, a quantitative detection method of T cell engaging bispecific antibody based on bioluminescent reporter gene is provided, and the quantitative detection method comprises:

[0030] Constructing target cells and effector cells; adding a sample to be tested thereto for incubation, wherein the target cells are Raji cells (CD19), the effector cells are Jurkat cells (CD3), and the effector cells are luciferase Jurkat-luc cells regulated by the IL-2 promoter;

[0031] The luciferase signal is detected to indicate T cell engagement of the bispecific antibody.

[0032] The sample to be tested may be a biological sample containing or suspected of containing a T cell engaging bispecific antibody, such as plasma, serum, etc., preferably serum.

[0033] The incubation time is 15-25h, preferably 18h.

[0034] The T cell engaging bispecific antibody is belintox.

[0035] In another specific embodiment of the present invention, the specific method for constructing Jurkat-luc cells expressing luciferase regulated by the IL-2 promoter includes: subcloning the IL-2 promoter response element into a lentiviral expression vector upstream of the minimal CMV promoter and the luciferase gene, performing lentiviral transfection on Jurkat cells, isolating and screening single clones (Jurkat-luc) that induce expression of luciferase, and screening the monoclonal cells with the highest luciferase intensity.

[0036] Wherein, the IL-2 promoter response element has a nucleotide sequence as shown in SEQ ID NO.1.

[0037] In another specific embodiment of the present invention, the application of the above quantitative detection method in the pharmacokinetic study of T cell engaging bispecific antibodies is provided.

[0038] Wherein, the T cell engaging bispecific antibody may be belintox.

[0039] The present invention is further explained by the following examples, but they are not intended to limit the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The test methods for the specific conditions in the following examples are usually carried out under normal conditions.

[0040] Example

[0041] 1. Construction of Jurkat-luc cell line expressing luciferase regulated by IL-2 promoter

[0042] The IL-2 promoter response element was subcloned into the minimal CMV promoter and the lentiviral expression vector GV715PGC-Fu-firefiy-Luciferase-SV40-puromycin upstream of the luciferase gene by standard molecular biological methods (purchased from GeneCare Gene, the lentiviral expression vector map is shown in Figure 1 ). Jurkat cells were transfected with lentivirus, and single clones (Jurkat-luc) that induced the expression of luciferase were isolated and screened. The single clone with the highest luciferase intensity (Jurkat-luc E) was screened ( Figure 2 ) for subsequent experiments.

[0043] Wherein, the specific nucleotide sequence of the IL-2 promoter response element is as follows:

[0044] GGATCCAGATCTATCACCCTGTGTGCAATTAGCTCATTGTGTAGATAAGAAGGTAAAACCATCTTGAAACAGGAAACCAATATCCTTCCTGTCTAATCAACAAATCTAAAAGATTTATTCTTTTCATCTATCTCCTCTTGCGTTTG TCCACCACAACAGGCTGCTTACAGGTTCAGGATGGTTTTGACAAAGAGAACATTTTCATGAGTTACTTTTGTGTCTCCACCCAAAGAGGAAAATTTGTTTCATACAGAAGGCGTTCATTGTATGAATTAAAACTGCCACCT AAGTGTGGGCTAACCCGACCAAGAGGGATTTCACCTAAATCCATTCAGTCAGTGTATGGGGGTTTTAAAGAAATTCCAGAGAGTCATCAGAAGAGGAAAAACAAAGGTAATGCTTTTTGCCACACAGGTAGACTCTTTGAAAA TATGTGTAATATGTAAAACATCGTGACACCCCCATATTATTTTTCCAGCATTAACAGTATAAATTGCCTCCCATGCTGAAGAGCTGCCTATCACCCTTGCTAAGCTTGGATCTGAGCTTGGCATTCCGGTACTGTTGGTAAA GCTAGC (SEQ ID NO.1)

[0045] The black underlined part is the restriction site, and the rest is the promoter sequence. The restriction site is BamHI / NheI.

[0046] 2. Validation of the dose-effect relationship of Jurkat-luc cell activation

[0047] After incubation of Jurkat-luc cells with gradient concentrations of nonspecific mitogenic PHA (lymphocyte activator) for 18 h, the bioluminescence intensity was detected using a luciferase reporter kit. The production of luciferase increased in a dose-dependent manner with PHA ( Figure 3 ), proving that there is a dose-effect relationship between the constructed cell line and cell activation.

[0048] 3. Validation of the dose-effect relationship between Jurkat-luc cells and Bellintosh

[0049] Raji cells (CD19) were used as target cells and Jurkat-luc cells (CD3) were used as effector cells. After being co-incubated with belintox at gradient concentrations for 18 hours, the bioluminescence intensity was detected using a luciferase reporter kit. The production of luciferase increased in a dose-dependent manner with belintox, proving that there was a dose-effect relationship between the Jurkat-luc cell line and belintox.

[0050] 4. Determination of Bellintosh Blood Sample Conditions

[0051] Raji cells (CD19) were used as target cells and Jurkat-luc cells (CD3) were used as effector cells. After incubation with them for 18 hours with gradient concentrations of belinto-o containing different ratios of serum / plasma, the bioluminescence intensity was detected using a luciferase reporter kit. It has been verified that in the incubation conditions of target cells and effector cells, the higher the proportion of plasma contained, the lower the fluorescence intensity, and the highest fluorescence intensity can be achieved at a lower concentration ( Figure 5 ), it is difficult to support the establishment of the detection method. Under the same ratio, the RLU curve change trend of the serum sample is close to that of the pure culture medium ( Figure 6 ), and showed a trend similar to plasma, where the higher the content ratio, the lower the fluorescence intensity ( Figure 7 ). Therefore, the final detection method selected serum sample detection, and the appropriate serum ratio was selected according to the concentration range required for detection.

[0052] 5. Methodological Validation of the Detection Method

[0053] Raji cells (CD19) were used as target cells and Jurkat-luc cells (CD3) were used as effector cells. Raji cell lines and Jurkat-luc cell lines were co-incubated with patient serum. High concentration samples were pre-diluted to ensure that the measured values ​​were within the detection range of the assay. A calibration test was performed with a standard series of Bellinto-O dilutions containing 20% ​​serum, and blank samples were used to measure serum background reactions. After incubating target cells and effector cells with blank serum, standard serum, or patient serum samples for 18 hours, luciferase reporter gene detection reagent was added, and the bioluminescence intensity was detected using a multifunctional microplate reader or other instrument capable of detecting chemiluminescence.

[0054] The serum drug concentration range that this method can detect is 50ng / mL-1000ng / mL. The standard curve is set with 13 points for curve fitting, and 3 positioning points are set at the top and bottom. The back calculation deviation of the standard curve is -1.12-11.01% ( Figure 8 , Table 1, 2).

[0055] Table 1 Back-calculated concentration and deviation of standard curve

[0056]

[0057]

[0058] The accuracy of this method is 85.94-100.17%, the precision is 0.10-6.21%, and the total error is 4.68-14.16%.

[0059] Table 2 Accuracy, precision and total error of the method

[0060]

[0061] Matters not covered by the present invention are known technologies.

[0062] The above embodiments are only for illustrating the technical concept and features of the present invention, and their purpose is to enable people familiar with the technology to understand the content of the present invention and implement it accordingly, and they cannot be used to limit the protection scope of the present invention. Any equivalent changes or modifications made according to the spirit of the present invention should be included in the protection scope of the present invention.

Claims

1. A quantitative detection method for T cell engaging bispecific antibodies based on bioluminescent reporter genes, characterized in that: The quantitative detection method comprises: Constructing target cells and effector cells; adding a sample to be tested thereto for incubation, wherein the target cells are Raji cells (CD19), the effector cells are Jurkat cells (CD3), and the effector cells are luciferase Jurkat-luc cells regulated by the IL-2 promoter; The luciferase signal is detected to indicate T cell engagement of the bispecific antibody.

2. The quantitative detection method according to claim 1, characterized in that The sample to be tested is a biological sample containing or suspected of containing the T cell engaging bispecific antibody.

3. The quantitative detection method according to claim 2, characterized in that: The biological samples include plasma and serum.

4. The quantitative detection method according to claim 3, characterized in that: The biological sample is serum.

5. The quantitative detection method according to claim 1, characterized in that: The incubation time is 15-25h.

6. The quantitative detection method according to claim 5, characterized in that: The incubation time was 18 h.

7. The quantitative detection method according to claim 1, characterized in that: The T cell engaging bispecific antibody is belintox.

8. The quantitative detection method according to claim 1, characterized in that: The specific method for constructing Jurkat-luc cells expressing luciferase regulated by the IL-2 promoter includes: subcloning the IL-2 promoter response element into a lentiviral expression vector upstream of the minimal CMV promoter and the luciferase gene, performing lentiviral transfection on Jurkat cells, isolating and screening single clones that induce expression of luciferase, and screening the single clone cells with the highest luciferase intensity; Furthermore, the IL-2 promoter response element has a nucleotide sequence as shown in SEQ ID NO.

1.

9. Use of the quantitative detection method according to any one of claims 1 to 8 in the pharmacokinetic study of T cell engaging bispecific antibodies.

10. The use according to claim 9, characterized in that: The T cell engaging bispecific antibody is belintox.

Citation Information

Patent Citations

  • Method for detecting cell biological activity of bispecific antibody

    CN117757886A

  • Methods for assaying t-cell dependent bispecific antibodies

    US20200182882A1